• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期毒性预测高级别胶质瘤的长期生存。

Early toxicity predicts long-term survival in high-grade glioma.

机构信息

Department of Radiation Oncology, Thomas Jefferson University, Kimmel Cancer Center, Bodine Cancer Center, 111 S. 11th Street, Philadelphia, PA 19107, USA.

出版信息

Br J Cancer. 2011 Apr 26;104(9):1365-71. doi: 10.1038/bjc.2011.123. Epub 2011 Apr 12.

DOI:10.1038/bjc.2011.123
PMID:21487410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3101937/
Abstract

BACKGROUND

Patients with high-grade gliomas are treated with surgery followed by chemoradiation. The risk factors and implications of neurological side effects are not known.

METHODS

Acute and late ≥ grade 3 neurological toxicities (NTs) were analysed among 2761 patients from 14 RTOG trials accrued from 1983 to 2003. The association between acute and late toxicity was analysed using a stepwise logistic regression model. The association between the occurrence of acute NT and survival was analysed as an independent variable.

RESULTS

There were 2610 analysable patients (86% glioblastoma, 10% anaplastic astrocytoma). All received a systemic agent during radiation (83% chemotherapy, 17% biological agents). Median radiation dose was 60 Gy. There were 182 acute and 83 late NT events. On univariate analysis, older age, poor performance status, aggressive surgery, pre-existing neurological dysfunction, poor mental status and twice-daily radiation were associated with increased acute NT. In a stepwise logistic regression model the occurrence of acute NT was significantly associated with late NT (OR=2.40; 95% CI=1.2-4.8; P=0.014). The occurrence of acute NT predicted poorer overall survival, independent of recursive partitioning analysis class (median 7.8 vs 11.8 months).

INTERPRETATION

Acute NT is significantly associated with both late NT and overall survival.

摘要

背景

高级别脑胶质瘤患者接受手术联合放化疗治疗。目前尚不清楚神经毒性的风险因素及其影响。

方法

本研究分析了 1983 年至 2003 年期间 14 项 RTOG 试验共 2761 例患者的急性和迟发性≥3 级神经毒性(NTs)。采用逐步逻辑回归模型分析急性和迟发性毒性之间的相关性。将急性 NT 的发生作为独立变量分析其与生存的关系。

结果

可分析的患者有 2610 例(86%为胶质母细胞瘤,10%为间变性星形细胞瘤)。所有患者在放疗期间均接受了全身治疗(83%为化疗,17%为生物制剂)。中位放疗剂量为 60Gy。发生急性 NT 有 182 例,迟发性 NT 有 83 例。单因素分析显示,年龄较大、一般状况较差、积极的手术、术前存在神经功能障碍、精神状态较差和每日 2 次放疗与急性 NT 增加相关。逐步逻辑回归模型中,急性 NT 的发生与迟发性 NT 显著相关(OR=2.40;95%CI=1.2-4.8;P=0.014)。急性 NT 的发生与总体生存显著相关,独立于递归分区分析类别(中位生存时间分别为 7.8 个月和 11.8 个月)。

结论

急性 NT 与迟发性 NT 和总体生存均显著相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c970/3101937/facb36ea2f6a/bjc2011123f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c970/3101937/e6c1294bb12c/bjc2011123f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c970/3101937/facb36ea2f6a/bjc2011123f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c970/3101937/e6c1294bb12c/bjc2011123f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c970/3101937/facb36ea2f6a/bjc2011123f2.jpg

相似文献

1
Early toxicity predicts long-term survival in high-grade glioma.早期毒性预测高级别胶质瘤的长期生存。
Br J Cancer. 2011 Apr 26;104(9):1365-71. doi: 10.1038/bjc.2011.123. Epub 2011 Apr 12.
2
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.调强放疗和替莫唑胺治疗新诊断的胶质母细胞瘤和间变星形细胞瘤:在调强放疗和替莫唑胺时代验证放射治疗肿瘤学组递归分区分析。
J Neurooncol. 2011 Aug;104(1):339-49. doi: 10.1007/s11060-010-0499-8. Epub 2010 Dec 22.
3
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.卡莫司汀同步超分割及加速超分割放疗治疗幕上恶性胶质瘤成人患者的Ⅰ/Ⅱ期试验最终报告。放射治疗肿瘤学组83-02研究。
Cancer. 1996 Apr 15;77(8):1535-43. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1535::AID-CNCR17>3.0.CO;2-0.
4
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
5
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.NOA-04 间变性胶质瘤序贯放化疗(采用丙卡巴肼、洛莫司汀和长春新碱或替莫唑胺)的随机 III 期试验
J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9.
6
High-grade gliomas: results in patients treated with adjuvant radiotherapy alone and with adjuvant radio-chemotherapy.高级别胶质瘤:单纯辅助放疗及辅助放化疗患者的治疗结果
Anticancer Res. 2006 May-Jun;26(3B):2429-35.
7
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.对高级别胶质瘤采用78 Gy的大剂量放疗,联合或不联合替莫唑胺。
J Neurooncol. 2009 Jul;93(3):343-8. doi: 10.1007/s11060-008-9779-y. Epub 2009 Jan 14.
8
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.手术、放疗及替莫唑胺治疗高级别胶质瘤
Front Biosci. 2006 May 1;11:1280-3. doi: 10.2741/1881.
9
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.使用氨基酸正电子发射断层扫描(单光子发射计算机断层扫描)/计算机断层扫描/磁共振成像图像融合技术对复发性高级别胶质瘤进行再照射,以确定立体定向分割放射治疗的大体肿瘤体积。
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9. doi: 10.1016/j.ijrobp.2005.01.056.
10
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.替莫唑胺用于新诊断的幕上恶性胶质瘤患者放疗前的II期研究。
Neuro Oncol. 2002 Oct;4(4):261-7. doi: 10.1093/neuonc/4.4.261.

引用本文的文献

1
Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRI.利用人工智能驱动的代谢和扩散磁共振成像预测胶质母细胞瘤复发进行新型放射治疗靶区定义。
NPJ Digit Med. 2025 Aug 7;8(1):508. doi: 10.1038/s41746-025-01861-2.
2
The impact of timing of temozolomide chemoradiotherapy for newly diagnosed glioblastoma on patient overall survival: A multicenter retrospective study.替莫唑胺同步放化疗时机对新诊断胶质母细胞瘤患者总生存期的影响:一项多中心回顾性研究。
Neurooncol Adv. 2024 Nov 12;6(1):vdae194. doi: 10.1093/noajnl/vdae194. eCollection 2024 Jan-Dec.
3
Metabolic management of microenvironment acidity in glioblastoma.

本文引用的文献

1
Evaluating the older patient with cancer: understanding frailty and the geriatric assessment.评估老年癌症患者:了解虚弱和老年评估。
CA Cancer J Clin. 2010 Mar-Apr;60(2):120-32. doi: 10.3322/caac.20059. Epub 2010 Feb 19.
2
Radiation dose-volume effects in the brain.脑的放射剂量-体积效应。
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7. doi: 10.1016/j.ijrobp.2009.02.091.
3
CNS complications of radiotherapy and chemotherapy.放疗和化疗的中枢神经系统并发症
胶质母细胞瘤微环境酸度的代谢管理
Front Oncol. 2022 Aug 17;12:968351. doi: 10.3389/fonc.2022.968351. eCollection 2022.
4
SIRT in 2025.SIRT 在 2025 年。
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1622-1633. doi: 10.1007/s00270-022-03228-6. Epub 2022 Aug 8.
5
Brain radiotoxicity-related 15CAcBRT gene expression signature predicts survival prognosis of glioblastoma patients.脑放射性毒性相关的 15CAcBRT 基因表达谱预测胶质母细胞瘤患者的生存预后。
Neuro Oncol. 2023 Feb 14;25(2):303-314. doi: 10.1093/neuonc/noac171.
6
Association between microRNAs 10b/21/34a and acute toxicity in glioblastoma patients treated with radiotherapy and temozolomide.miRNA 10b/21/34a 与替莫唑胺联合放疗治疗胶质母细胞瘤患者急性毒性的相关性。
Sci Rep. 2022 May 7;12(1):7505. doi: 10.1038/s41598-022-11445-9.
7
Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model.钇-90放射性栓塞术作为一种可能的脑癌新疗法:犬模型中的概念验证和安全性分析
EJNMMI Res. 2020 Aug 17;10(1):96. doi: 10.1186/s13550-020-00679-1.
8
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.老年新诊断胶质母细胞瘤的治疗:一项网状Meta分析
Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261. doi: 10.1002/14651858.CD013261.pub2.
9
O-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma.O-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化和异柠檬酸脱氢酶突变作为沙特胶质母细胞瘤患者队列中的预后因素。
Ann Saudi Med. 2019 Nov-Dec;39(6):410-416. doi: 10.5144/0256-4947.2019.410. Epub 2019 Dec 5.
10
Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?挑衅性问题:生酮代谢疗法是否应该成为胶质母细胞瘤的标准治疗方法?
Neurochem Res. 2019 Oct;44(10):2392-2404. doi: 10.1007/s11064-019-02795-4. Epub 2019 Apr 25.
Lancet. 2009 Nov 7;374(9701):1639-51. doi: 10.1016/S0140-6736(09)61299-X.
4
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.同步放化疗联合辅助替莫唑胺与单纯放疗对胶质母细胞瘤生存影响的随机III期研究:EORTC-NCIC试验的5年分析
Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.
5
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.在放射治疗中添加替莫唑胺对假性进展发生率的影响。
J Neurooncol. 2009 Aug;94(1):97-101. doi: 10.1007/s11060-009-9809-4. Epub 2009 Feb 17.
6
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.新诊断胶质母细胞瘤的I期三维适形放射剂量递增研究:放射治疗肿瘤学组98-03试验
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):699-708. doi: 10.1016/j.ijrobp.2008.05.034. Epub 2008 Aug 23.
7
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.恶性胶质瘤假性进展的临床特征、机制及处理
Lancet Oncol. 2008 May;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6.
8
Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis.多形性胶质母细胞瘤辅助化疗的临床影响:一项荟萃分析。
CNS Drugs. 2007;21(9):775-87. doi: 10.2165/00023210-200721090-00006.
9
Radiotherapy for glioblastoma in the elderly.老年胶质母细胞瘤的放射治疗
N Engl J Med. 2007 Apr 12;356(15):1527-35. doi: 10.1056/NEJMoa065901.
10
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.胶质母细胞瘤患者同步使用替莫唑胺和放疗后的早期坏死。
J Neurooncol. 2007 Mar;82(1):81-3. doi: 10.1007/s11060-006-9241-y. Epub 2006 Aug 31.